Latigo Biotherapeutics, Inc.

Latigo Biotherapeutics, Inc. develops non-opioid pain medicines that aim to block pain transmission without the risk of addiction. The company's product pipeline includes LTG-001, an oral NaV1.8 inhibitor intended to offer fast-acting, opioid-sparing relief for acute pain. Another candidate, LTG-321, is a NaV1.8 inhibitor being developed for chronic musculoskeletal pain, with an initial focus on osteoarthritis. Additionally, LTG-418 is a NaV1.8 inhibitor designed for both acute and chronic pain treatment. Latigo Biotherapeutics, Inc. was incorporated in 2018 and is headquartered in Thousand Oaks, California. The company was previously known as WVB-Desmond, Inc. and adopted the name Latigo Biotherapeutics, Inc. in March 2019.